Dupilumab-Associated Cutaneous Adverse Events Among Adult Patients With Atopic Dermatitis: A Retrospective Study

This retrospective study analyzed cutaneous adverse events (cAEs) in 916 adult patients treated with dupilumab for atopic dermatitis at the University Federico II of Naples. The study found that 16.15% of patients experienced cAEs, including facial redness (8.95%), psoriasis (4.25%), alopecia areata (1.2%), skin peeling (1.2%), parapsoriasis (0.32%), and vitiligo (0.21%). Despite these events, only 3.38% of patients discontinued treatment due to cAEs, with most cases being mild. These findings help dermatologists better understand and manage the cutaneous side effects of dupilumab in clinical practice.